Pharma Q4 Outlook: Steady Hospital Performance Meets Challenges from Revlimid’s Generic Competition.

The pharmaceutical and healthcare sector is poised for a varied performance in the upcoming March quarter, as highlighted by ET Intelligence Group. Hospital chains are anticipated to show steady growth, with companies like Apollo Hospitals expected to maintain resilient traction across hospitals, pharmacies, and diagnostics. The positive outlook is bolstered by new bed additions and improved patient revenue. Conversely, generic drug manufacturers are experiencing challenges, particularly with the decline in Revlimid-related sales affecting key players like Aurobindo Pharma and Dr. Reddy’s. Despite these hurdles, several firms within the sector, such as Lupin and Divi’s Laboratories, are expected to report strong revenue growth driven by diversified product portfolios and effective contract development demand.

Lupin is set to benefit significantly from strong sales in the US, driven by therapies in areas like chronic diseases while maintaining robust domestic growth. The projected 50% year-on-year jump in Ebitda supports this positive outlook, although margins may face pressure due to increasing R&D expenditures. Similarly, Divi’s Laboratories is projected to see double-digit revenue growth, driven by custom synthesis and a recovery in nutraceuticals despite the decline in generic API sales. The overall landscape reveals that while some companies, including Torrent and Sun Pharma, are expected to post steady growth through diversified portfolios and strong domestic demand, others are grappling with the ramifications of patent expirations and competitive pressures in key markets.

Aurobindo Pharma and Dr. Reddy’s are expected to confront significant obstacles with their revenues, particularly due to the absence of sales from gRevlimid and other competitive pressures. For Dr. Reddy’s, the anticipated decline in Ebitda of 28-30% indicates challenges in maintaining margins, particularly with the changes in the Canadian market regarding semaglutide. A similar pattern is observed with Cipla, where competition and supply disruptions are expected to weigh heavily on its US and Indian sales. Overall, while the sector displays a mixed bag of growth across various companies, the key monitorables going forward will include market performance in specialty products, the ramp-up of production facilities, and the ongoing adjustments to regulatory requirements impacting these pharmaceutical entities.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)